RxDoctor Payments Data

Payal Pardiwala

Family · Turlock, CANPI 1902413198

Payments from drug & device makers

$2,719in general payments, 2019–2025

Across 122 payments — averaging $22.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$663
  • AbbVie$428
  • Incyte Corporation$325
  • Regeneron Healthcare Solutions, Inc.$242
  • Sun Pharmaceutical Industries Inc.$176
  • Revance Therapeutics, Inc.$115
  • plus $770 from 19 others

What the payments were for

  • Food & beverage$2,52093%
  • Education$1997%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,719 in reported general payments places this provider in the 85th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$126,660
Medicare patients
290
Services billed
2,331

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab26$92,857
OtezlaApremilast15$68,266
Tacrolimus27$4,263
Azelaic Acid16$2,380
Fluocinonide44$2,370
Clobetasol Propionate77$2,293
Ketoconazole110$1,791
Tretinoin22$1,596
Desonide24$1,360
Fluorouracil12$1,175
Metronidazole28$1,149
Betamethasone Dipropionate18$692
Clindamycin Phosphate19$679
Triamcinolone Acetonide80$485
Doxycycline Monohydrate18$305

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$46$68,26615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,634 family providers in California.

Other family in Turlock

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →